文献速递流行病学与生物统计真实世界研究与卫生经济

生活方式与二甲双胍干预对糖尿病前期成人多病共存风险的影响

Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes.
PubMed 文献 · JAMA · 2026-01-01

该研究基于美国糖尿病预防计划(DPP)及其结局研究(DPPOS)的观察性随访队列,纳入1173名基线糖尿病前期成人,比较强化生活方式干预、二甲双胍与安慰剂对长期多病共存(≥2种慢性病)的影响。结果显示,生活方式干预组多病共存风险显著低于安慰剂组(HR 0.79;95%CI 0.68-0.93),而二甲双胍组与安慰剂组无差异(HR 0.91;95%CI 0.78-1.07)。

要点

  • 生活方式干预与糖尿病前期成人多病共存风险降低相关(HR 0.79)。
  • 二甲双胍未显示降低多病共存风险(HR 0.91)。
  • 生活方式干预对高成本疾病组合的风险降低更明显(HR 0.57)。

核心结论

  • 在糖尿病前期成人中,生活方式干预而非二甲双胍与较低的多病共存负担相关。

研究设计与样本

  • DPP纳入3234名糖尿病高风险成人,其中1173名参与者有CMS发病率数据可供分析。
  • 参与者被随机分配至强化生活方式干预、二甲双胍或安慰剂组。

主要发现

  • 中位随访至74岁时,1173名参与者中997名(85%)发生≥2种慢性病。
  • 生活方式组多病共存风险低于安慰剂组(HR 0.79;95%CI 0.68-0.93)。
  • 二甲双胍组与安慰剂组多病共存风险无差异(HR 0.91;95%CI 0.78-1.07)。
  • 排除糖尿病后,上述关联持续存在。
  • 限于高成本疾病组合时,生活方式 vs 安慰剂的HR为0.57(95%CI 0.38-0.85)。

临床怎么用

  • 对于糖尿病前期成人,生活方式干预可能长期降低多病共存风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Studying how to prevent or delay not just 1 disease but multiple chronic conditions is of great importance for public health; however, few interventions have demonstrated success during long-term follow-up. OBJECTIVE: To examine the association of lifestyle or metformin compared with placebo on long-term multimorbidity in adults with prediabetes. DESIGN, SETTING, AND PARTICIPANTS: Observational follow-up cohort study of a randomized clinical trial conducted at 27 sites in the United States from June 1, 1996, to December 31, 2021. From June 1, 1996, through May 28, 1999, 3234 adults at high risk of diabetes enrolled in the 3-year Diabetes Prevention Program (DPP). They were subsequently enrolled in the DPP Outcomes Study (DPPOS). Of this cohort, Centers for Medicare & Medicaid Services (CMS) morbidity data were available through 2021 for 1173 participants who provided consent. Data were analyzed from June 5, 2024, to November 7, 2025. EXPOSURES: Participants in DPP were randomly assigned to intensive lifestyle intervention, metformin, or placebo. During DPPOS, medications were unmasked with discontinuation of placebo; metformin was continued. Group booster classes were offered to the lifestyle group semiannually and all participants were offered lifestyle classes quarterly until 2014. MAIN OUTCOMES AND MEASURES: The primary outcome was multimorbidity (presence of ≥2 of 15 prevalent conditions, defined in CMS' Chronic Condition Data Warehouse and adapted for Medicare Advantage encounters). Cox proportional hazard models were applied to estimate associations between randomized treatment groups and time to development of outcomes. RESULTS: Of the 1173 participants (median age, 74 years [IQR, 70-80]; 795 [68%] were female), 997 (85%) experienced greater than or equal to 2 conditions (median, 5 [IQR, 3-7]) by the end of follow-up (316 of 385 [82%], 327 of 385 [85%], and 350 of 403 [87%], respectively, among lifestyle, metformin, and placebo groups). The risk of multimorbidity was lower among lifestyle compared with placebo participants (hazard ratio [HR], 0.79; 95% CI, 0.68-0.93) after adjustment for relevant covariates. There was no difference between participants in the metformin and placebo groups (HR, 0.91; 95% CI, 0.78-1.07). These relationships persisted when diabetes was excluded from the multimorbidity definition. When restricted to dyads of the costliest conditions, the association with lifestyle vs placebo yielded an HR of 0.57 (95% CI, 0.38-0.85). CONCLUSIONS AND RELEVANCE: Among adults with prediabetes at baseline, lifestyle intervention, but not metformin, was associated with a lower burden of multimorbidity. Lifestyle programs may persistently lower the development of chronic conditions. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: DPP, NCT00004992; DPPOS, NCT00038727.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Salive ME, Tjaden AH, Ames JR, et al. Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes. JAMA. 2026. PMID: 42295772. doi:10.1001/jama.2026.8492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。